1. Home
  2. TLS vs CRVS Comparison

TLS vs CRVS Comparison

Compare TLS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$5.76

Market Cap

463.8M

Sector

Technology

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$9.12

Market Cap

459.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
CRVS
Founded
1969
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
459.0M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
TLS
CRVS
Price
$5.76
$9.12
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$7.75
$13.75
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$144,400,000.00
N/A
Revenue This Year
$47.80
N/A
Revenue Next Year
$26.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.44
N/A
52 Week Low
$1.83
$2.54
52 Week High
$8.36
$9.55

Technical Indicators

Market Signals
Indicator
TLS
CRVS
Relative Strength Index (RSI) 41.42 66.22
Support Level $5.68 $8.49
Resistance Level $5.99 $9.32
Average True Range (ATR) 0.55 0.51
MACD -0.04 0.02
Stochastic Oscillator 13.26 87.50

Price Performance

Historical Comparison
TLS
CRVS

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: